Table 2.
Demographic characteristics, clinicopathological features and treatments performed in 140 patients with malignant pancreatic neuroendocrine tumours undergoing a radical resection (group A), palliative resection (group B) or without resection (group C)
| Characteristic | Group A (n = 76) | Group B (n = 22) | Group C (n = 42) | P-value |
|---|---|---|---|---|
| Male | 40 | 12 | 25 | 0.797 |
| Age (mean), years | 56.9 | 62.7 | 60.6 | 0.840 |
| Non-functioning | 67 | 17 | 40 | 0.095 |
| Symptomatic | 34 | 12 | 35 | 0.000 |
| Primary tumour diameter (mean), mm | 43.4 | 45.0 | 42.1 | 0.018 |
| Tumour site: | ||||
| Pancreatic head | 25 | 8 | 19 | 0.048 |
| Pancreatic body-tail | 46 | 14 | 21 | 0.234 |
| Pancreatic diffuse | 5 | 0 | 2 | (*) |
| Lymph node metastases | 47 | 15 | 27 | 0.861 |
| Hepatic metastases | 9 | 21 | 36 | 0.000 |
| Liver resection | 9 | 13 | 0 | 0.000 |
| Somatostatin analogues | 19 | 18 | 26 | 0.408 |
| PRRT | 2 | 1 | 11 | (*) |
| Ablative treatments | 3 | 8 | 4 | (*) |
| Chemotherapy | 13 | 2 | 15 | 0.042 |
(*) not applicable due to the small numbers. Bold indicates significant P-value.
PRRT, peptide receptor radio therapy.